Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Tafamidis 61 mg. Diese Vereinbarung gilt nur für die Indikation Transthyretin-Amyloidose mit Kardiomyopathie vom hereditären Typ (ATTRh-CM).

TENDER DESCRIPTION

GWQ ServicePlus AG intends to conclude non-exclusive discount agreements pursuant to Section 130a(8) of SGB V for the above-mentioned active ingredient with a contract start date of 15.12.2026. All interested companies may join this contract at any time during the contract term under the same conditions (access model based on approval). GWQ assumes that, due to the absence of a selection decision and thus the non-discriminatory possibility of access for all pharmaceutical companies, this procedure does not fall within the scope of cartel procurement law. The contract documents, the participating health insurance funds and their sales as well as the deadlines for the notification of the contract can be viewed and downloaded from the procurement portal of GWQ ServicePlus AG at https://vergabeportal.gwq-serviceplus.de/arzneimittel. Until the start of exclusive contracts, this transitional agreement is open to all market participants to join. Upon receipt of the signed contracts / declaration and evidence by 25.11.2026, an initial notification can be made for 15.12.2026. The following documents must be submitted: the signed contract in duplicate; evidence of marketing authorisation…

TENDER BRIEF

TENDER DOCUMENTS